Indicated for: Parkinson's disease
Route of administration: infusion
Substance: foslevodopa + foscarbidopa (antiparkinsonian agents)
ATC: N04BA07 (Nervous system | Dopaminergic agents | Dopa and dopa derivatives)
Foslevodopa and foscarbidopa are two medications used together in the treatment of Parkinson's disease. Foslevodopa is a soluble form of levodopa that helps increase dopamine levels in the brain, thereby improving symptoms of Parkinson's disease such as tremors, stiffness, and movement difficulties. Foscarbidopa is given alongside to prevent the premature breakdown of levodopa, enhancing the effectiveness of the treatment.
This therapy is usually administered as a continuous infusion, allowing for better control of symptoms throughout the day. The dosage and method of administration are determined by the doctor, based on the patient's individual needs and response to treatment.
Side effects may include nausea, vomiting, dizziness, insomnia, or low blood pressure. In some cases, involuntary movements or mood changes may occur. It is important for patients to report any adverse reactions to their doctor so the treatment can be adjusted as needed.
Foslevodopa and foscarbidopa offer a modern option for patients with advanced Parkinson's disease, providing significant symptom relief and improving quality of life. Close monitoring and collaboration with the medical team are essential for successful treatment.